NCT06824103 - Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

November 29, 2029

Study Completion Date

January 11, 2032

Conditions

Graft vs. Host DiseaseChronic Graft vs. Host DiseaseCorticosteroid-refractory Chronic Graft vs. Host Disease

Interventions

DRUG

Ruxolitinib

Ruxolitinib is taken orally daily at 10 mg BID, given as two 5 mg tablets.

Trial Locations (9)

RECRUITING

Novartis Investigative Site, Hefei

RECRUITING

Novartis Investigative Site, Hangzhou

RECRUITING

Novartis Investigative Site, Zhejiang

RECRUITING

Novartis Investigative Site, Wenzhou

RECRUITING

Novartis Investigative Site, Changsha

RECRUITING

Novartis Investigative Site, Zhengzhou

RECRUITING

Novartis Investigative Site, Guangzhou

RECRUITING

Novartis Investigative Site, Guangzhou

RECRUITING

Novartis Investigative Site, Shijiazhuang